Omnicell (OMCL) to Release Quarterly Earnings on Thursday

Omnicell (NASDAQ:OMCL) is expected to release its Q4 2025 results before the market opens on Thursday, February 5th. Analysts expect Omnicell to post earnings of $0.47 per share and revenue of $313.3560 million for the quarter. Investors can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, February 5, 2026 at 8:30 AM ET.

Omnicell Price Performance

OMCL opened at $46.04 on Wednesday. The company has a current ratio of 1.44, a quick ratio of 1.21 and a debt-to-equity ratio of 0.14. The company has a market cap of $2.07 billion, a price-to-earnings ratio of 107.07, a price-to-earnings-growth ratio of 5.19 and a beta of 0.78. The stock has a fifty day simple moving average of $45.96 and a two-hundred day simple moving average of $36.84. Omnicell has a 12-month low of $22.66 and a 12-month high of $55.00.

Insider Buying and Selling

In other Omnicell news, EVP Corey J. Manley sold 6,106 shares of Omnicell stock in a transaction on Thursday, January 8th. The stock was sold at an average price of $49.90, for a total value of $304,689.40. Following the completion of the sale, the executive vice president owned 91,674 shares of the company’s stock, valued at approximately $4,574,532.60. This trade represents a 6.24% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 2.52% of the company’s stock.

Institutional Investors Weigh In On Omnicell

Several large investors have recently bought and sold shares of OMCL. Raymond James Financial Inc. bought a new position in Omnicell during the 2nd quarter valued at about $26,000. Tower Research Capital LLC TRC grew its stake in shares of Omnicell by 385.5% in the second quarter. Tower Research Capital LLC TRC now owns 4,952 shares of the company’s stock worth $146,000 after acquiring an additional 3,932 shares during the period. Schonfeld Strategic Advisors LLC purchased a new position in shares of Omnicell during the third quarter valued at approximately $209,000. Cerity Partners LLC bought a new position in Omnicell during the second quarter valued at approximately $211,000. Finally, CIBC Bancorp USA Inc. bought a new position in Omnicell during the third quarter valued at approximately $224,000. 97.70% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on OMCL. UBS Group set a $53.00 price target on shares of Omnicell in a research note on Friday, January 16th. Benchmark upped their price objective on shares of Omnicell from $50.00 to $60.00 and gave the stock a “buy” rating in a report on Monday. Zacks Research lowered shares of Omnicell from a “strong-buy” rating to a “hold” rating in a report on Tuesday, December 9th. Weiss Ratings reissued a “sell (d+)” rating on shares of Omnicell in a research report on Thursday, January 22nd. Finally, KeyCorp upgraded Omnicell from a “sector weight” rating to an “overweight” rating and set a $60.00 price target on the stock in a research note on Wednesday, January 7th. Four investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Omnicell has an average rating of “Hold” and a consensus target price of $50.00.

About Omnicell

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.